You are now leaving NeulastaHCP.com

Please be aware that the sponsors of this site are not responsible for content on the site you are about to enter.

Return to Previous Page Continue to External Site

About Febrile Neutropenia

Neutropenia can affect patients and their treatment in many ways. Clinical studies have shown that neutropenia can interrupt chemotherapy treatment. Patients who experience febrile neutropenia may also require hospitalization and subsequent post-discharge care.1-7

Prevalence of Clinically Significant Febrile Neutropenia

An estimated 60,000 cancer patients in the United States were hospitalized for chemotherapy-induced febrile neutropenia in 1999.8

See study results »

Dose Modification: Breast Cancer

View study results affecting the optimal delivery of chemotherapy in patients with breast cancer, in which neutropenia (both grade 3-4 and febrile) was the most frequent cause of chemotherapy dose delays and dose reductions.1,2

See study results »

Dose Modification: Non-Hodgkin's Lymphoma

Neutropenia can impact chemotherapy delivery in patients with non-Hodgkin's lymphoma (NHL), causing dose delays and dose reductions.3

See study results »

Interested in updates about febrile neutropenia?

Thank You.

Subscriber Information

Please note: If at any time you decide you no longer wish to receive information by e-mail, you will be able to unsubscribe.

The personal information you supply to us will be shared with and among our business partners to provide you with products, programs, and services regarding Amgen and to conduct market research. Your information may be combined with additional information from this or other Amgen-sponsored programs in which you participate. Your information will be used only by Amgen and business service companies working with us, and will not be sold or rented. If in the future you no longer want to receive materials, you may do so by following the unsubscribe link included in all such materials sent to you, or you may click here.

Terms of Use

For further information about Amgen privacy practices, please visit wwwext.amgen.com/privacy/statement.html to review our Privacy Statement.

References

  1. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524-4531.
  2. Link BK, Budd GT, Scott S, et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer. 2001;92:1354-1367.
  3. Lyman G, Dale D, Friedberg J, Crawford J, Fisher R. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin‘s lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302-4311.
  4. Picozzi V, Pohlman B, Morrison V, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin‘s lymphoma. Oncology. 2001;15:1296-1306.
  5. Vogel C, Wojtukiewicz M, Carroll R, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-1184.
  6. Neulasta® (pegfilgrastim) prescribing information, Amgen.
  7. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol. 2008;19:454-460.
  8. Caggiano V, Weiss R, Rickert T, Linde-Zwirble W. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916-1924.